Company: Kallyope Inc.
Headquarters: New York, New York, USA
Founded: 2015
Funding: $272 million (total)
Ownership: Private
Kallyope is a biotechnology company focused on understanding the gut-brain axis and developing therapeutics for neurological and metabolic diseases. The company was founded by leading scientists in the field of gut-brain communication and has built a proprietary platform to map the complex signaling between the gastrointestinal tract and the central nervous system[@kallyope].
The gut-brain axis represents one of the most exciting frontiers in neuroscience, with emerging evidence linking gut health to conditions ranging from [Parkinson's disease and [Alzheimer's disease to depression and anxiety. Kallyope's mission is to translate this scientific understanding into novel treatments for patients with serious neurological disorders.
The gut-brain axis is a bidirectional communication network connecting the gastrointestinal tract with the central nervous system:
Communication Pathways:
Kallyope has built an integrated platform combining:
Technologies:
Data Assets:
Kallyope has a significant focus on [Parkinson's disease, driven by the growing understanding of gut involvement in PD pathogenesis:
| Program | Target | Mechanism | Stage |
|---|---|---|---|
| K-141 | GBA | Gene therapy for GBA-associated PD | Preclinical |
| K-142 | LRRK2 | Small molecule LRRK2 modulator | Discovery |
| K-149 | Alpha-synuclein | Microbiome-targeted intervention | Discovery |
Kallyope's approach is grounded in the emerging hypothesis that Parkinson's disease may start in the gut:
Kallyope's programs aim to intervene at multiple points in this pathway.
| Program | Target | Mechanism | Stage |
|---|---|---|---|
| K-201 | APOE4 | Targeted intervention for APOE4 carriers | Discovery |
| K-205 | Microbiome | Microbial metabolite modulation | Preclinical |
Kallyope is also active in:
| Year | Round | Amount | Lead Investors |
|---|---|---|---|
| 2022 | Series C | $118M | The Column Group, Arch Venture |
| 2020 | Series B | $102M | Casdin Capital, Logos Capital |
| 2018 | Series A | $44M | Polaris Partners, The Column Group |
| 2016 | Seed | $8M | Various angels |
Kallyope has established collaborations with:
Kallyope was founded by renowned gut-brain scientists:
Kallyope operates in the emerging gut-brain axis therapeutics space:
Competitors:
Differentiation:
| Program | Indication | Stage | Modalities |
|---|---|---|---|
| K-141 | Parkinson's disease (GBA) | Preclinical | Gene therapy |
| K-142 | Parkinson's disease (LRRK2) | Discovery | Small molecule |
| K-149 | Parkinson's disease | Discovery | Microbiome |
| K-201 | Alzheimer's disease (APOE4) | Discovery | Biologic |
| K-205 | Alzheimer's disease | Preclinical | Microbiome |
| K-301 | Obesity | Phase 1 | Small molecule |